Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie Sets Out Expectations For 2024 Humira Competition

Offers Overview Of Anticipated Impact From Adalimumab Biosimilars In The Year Ahead

Executive Summary

As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.

You may also be interested in...



AbbVie: Humira Competition Has Gone ‘Exceptionally Well’ For Us

With adalimumab biosimilars slow to capture market share from Humira in the US, AbbVie says that erosion for the top-selling brand is continuing to go “exceptionally well” for the originator.

AbbVie Sets Biosimilar Expectations As It Prepares To Take The Plunge On Humira

AbbVie has set out its expectations for US biosimilar competition to Humira this year, predicting 37% brand erosion with pressures ramping up in the second half of 2023 as Amgen’s Amjevita is followed into the market by numerous other adalimumab rivals. Management also commented on pricing dynamics after Amgen offered a dual-discount strategy.

Canada Sees Face-Off Over Higher-Strength Adalimumab

Hot on the heels of rival Celltrion, Jamp and partner Alvotech have now launched their own higher-strength adalimumab biosimilar in Canada, setting up a showdown between their Simlandi version and Celltrion’s Yuflyma.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel